Potential Drug–Drug Interactions and Associated Factors among Outpatients with Coronary Heart Disease at Cempaka Putih Islamic Hospital, Jakarta
Isi Artikel Utama
Abstrak
Coronary heart disease (CHD) is a major cause of morbidity and mortality worldwide, and its pharmacological management often involves multiple medications that may increase the risk of potential drug–drug interactions (pDDIs). This study aimed to describe the profile of pDDIs and evaluate their associations with age, gender, number of medications, and comorbidities among outpatients with CHD at Jakarta Cempaka Putih Islamic Hospital. An analytical observational study with a retrospective cross-sectional design was conducted using medical records of 200 outpatients treated between January and March 2026. Total sampling was applied to eligible patients with complete medical records and concurrent use of at least two medications. Potential drug interactions were identified using Drugs.com and Medscape, while descriptive and bivariate analyses were performed using SPSS. Of the 200 patients, 190 (95.0%) had at least one potential drug interaction, with 848 drug-pair occurrences identified. Pharmacodynamic interactions predominated, accounting for 713 occurrences (84.1%), while pharmacokinetic interactions accounted for 135 (15.9%). Most interactions were classified as moderate in severity (782; 92.2%), followed by major (38; 4.5%) and minor interactions (28; 3.3%). Bisoprolol and candesartan constituted the most frequently identified interacting drug pair, with 68 occurrences (8.02%). Bivariate analysis revealed no statistically significant associations between pDDIs and age (p = 0.499), gender (p = 1.000), or number of medications (p = 0.603). However, cardiovascular disorders (p < 0.001) and other comorbidities (p = 0.017) were significantly associated with pDDIs, whereas hypertension, diabetes mellitus, dyslipidemia, and renal disorders were not. These findings demonstrate the high prevalence of potential drug interactions among CHD outpatients and emphasize the importance of routine medication review, systematic interaction screening, and appropriate clinical monitoring. Collaborative pharmaceutical care is essential to support rational prescribing and improve medication safety.
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Referensi
Aprillia, R., Sutrisno, D., & Andriani, M. (2025). Analisis Interaksi Obat Pada Pasien Penyakit Jantung Koroner Rawat Inap Di Rsud H. Abdul Manap Jambi Periode 2024. Jurnal Sinergi Teknologi Kesehatan Nusantara.
Asiimwe, I. G., & Pirmohamed, M. (2022). Drug-drug-gene interactions in cardiovascular medicine. Pharmacy and Pharmacogenomics Medicine, 15, 338601. https://doi.org/10.2147/pgpm.s338601
Astuti, L. W., Wulan, F. W., & Donna, N. B. (2024). Pasien Infark Miokard Akut pada Studi Penggunaan Obat Anti Platelet di RSUD Gambiran Kota Kediri. Jurnal Medika Nusantara, 2(1), 238-245.
Auliafendri, N. (2022). Evaluasi Interaksi Obat Jantung Koroner pada Pasien Rawat Inap di Rumah Sakit Umum Imelda Pekerja Indonesia Medan. JIFI (Jurnal Ilmiah Farmasi Imelda), 5(2), 43-50.
Ayuningsih, I. (2023). Potensi Kejadian Interaksi Obat pada Pasien Penyakit Jantung Koroner Rawat Jalan di Rumah Sakit Khusus Daerah Duren Sawit Tahun 2022.
Buldan, M. R. F., Yuniarni, U., & Lestari, F. (2023). Analisis Interaksi Obat Pada Pasien Rawat Jalan Penderita Penyakit Jantung Koroner di Salah Satu Rumah Sakit di Kota Bandung. Bandung Conference Series Pharmacy.
Chusna, N., Retnowati, E., & Husna, U. Y. (2026). Potensi Interaksi Obat Penyakit Jantung Koroner Pada Pasien Lansia Di Rawat Inap Rumah Sakit Islam Sunan Kudus. Journal of Innovative and Creativity, 6(1), 19535–19541.
Efriani, L., Irawan, A., & Anwar, M. (2024). Analisis drug related problems (DRPs) pada pasien angina pektoris RS X Kota Cirebon tahun 2023. Jurnal Farmasi (Journal of Pharmacy), 13(2), 42-51.
Endalifer, B. L., Kassa, M. T., Ejigu, Y. W., & Ambaye, A. S. (2025). Polypharmacy, drug-drug interactions, and potentially inappropriate medications among older adults: A cross-sectional study in Northeast Ethiopia. Frontiers in Public Health, 13, 1525079. https://doi.org/10.3389/fpubh.2025.1525079
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal-Cardiovascular Pharmacotherapy, 8(2), 105- 135. https://doi.org/10.1093/ehjcvp/pvac005
Fajariyani, A., Mariyana, T., & Rachamawati, P. (2024). Kajian Retrospektif Potensi Interaksi Obat Resep Polifarmasi pada Pasien Poli Jantung di Rumah Sakit X Di Karawang. The Journal General Health and Pharmaceutical Sciences Research, 2(2), 08–16. https://doi.org/10.57213/tjghpsr.v2i2.338
Febriyenti, A., Yosmar, R., & Permatasari, D. (2025). Cardiovascular drug-drug interactions (DDIs) in coronary heart disease patients with hypertension. Journal of Pharmacy and Pharmaceutical Sciences,8(4), 1074. https://doi.org/10.36490/journal-jps.com.v8i4.1074
Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., & Corsini, A. (2022). Drug-drug interactions of direct oral anticoagulants (DOACs): From pharmacological to clinical practice. Pharmaceutics, 14 (6), 1120. https://doi.org/10.3390/pharmaceutics14061120
Godoy, M., & Lima, T. A. M. (2024). Drug-drug interactions in hospitalized older adults with acute coronary syndrome: A real-world study in Brazil. GeroScience Today, e0000225. https://doi.org/10.53886/gga.e0000225_en
Humaira, N., Mursyid, M., & Zahran, I. (2023). Kajian Interaksi Obat pada Pasien Penyakit Jantung di RSUD St. Madyang Palopo. Jurnal Surya Medika, 9(3), 66–70. https://doi.org/10.33084/jsm.v9i3.6469
Humza, A. U., Siddiq, A., Baig, S., Ali, A., Ahmed, I., & Yousuf, J. B. (2024). Assessment of QTc-interval prolonging medication utilization and associated potential drug-drug interactions in hospitalized cardiac patients: A cross-sectional study in cardiology. Jordan Journal of Pharmaceutical Sciences, 17(3), 2136. https://doi.org/10.35516/jjps.v17i3.2136
Kaltimurti, G. C. (2023). Kajian potensi interaksi obat pada pengobatan jantung koroner pasien rawat jalan di Poli Jantung RSUD Ibu Fatmawati Soekarno Kota Surakarta Tahun 2022.
Khan, A., & Hussain, H. (2024). Evaluation of factors contributing to potential drug-drug interactions in cardiovascular disease management: A retrospective study. Health Frontier, 2(2), 202. https://doi.org/10.56578/hf020202
Marovi, I., Udovii, M., Rudan, D., Manola, Š., Samardi, I., Vrca, V., ... & Hadiabdi, M. O. (2024). Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission. Acta Pharmaceutica, 74(4), 0038. https://doi.org/10.2478/acph-2024-0038
Maulani, D. (2022). Potensi Interaksi Obat Bisoprolol Pada Pasien Bpjs Rawat Jalan Di Poli Jantung Rumah Sakit Al Huda Banyuwangi. Jurnal Ilmiah Farmasi Akademi Farmasi Jember, 5(2), 64-71.
Maulia, A. N., Kumala, M. T., & Rochmah, N. N. (2022). Kajian potensi interaksi obat pada pasien hipertensi di instalasi rawat jalan Rumah Sakit X periode Agustus 2019. Jurnal Ilmiah JOPHUS: Journal Of Pharmacy UMUS, 3(02), 111-119.
Meiliana, M. L., Resti, I. A., & Annisa, N. J. (2023). Profil Penggunaan Antidiabetes Dan Potensi Interaksi Obat Pada Pasien Diabetes Mellitus Tipe Ii Dengan Komplikasi Hipertensi Di Rs Tk. 02.07. 04 Bandar Lampung. Warta Farmasi, 12(2), 16-24.
Nasab, N. F., Rezaeian, S., Ezadi, S., & Khatony, A. (2025). Prevalence and determinants of polypharmacy: A cross-sectional study among elderly patients with cardiovascular diseases in outpatient clinics. Science International, 5, 6641747. https://doi.org/10.1155/sci5/6641747
Nugroho, A. W., Tajudin, T., & Kurniawati, M. (2024). Analisis Potensi Interaksi Obat Pasien Rawat Inap Covid-19 Dengan Komorbid Diabetes Melitus Di Rs Pku Muhammadiyah Wonosobo. JURNAL FARMAMEDIKA (Pharmamedica Journal), 9(1), 1–8.
Nur Hidayati, L. (2022). Gambaran Interaksi Obat Penyakit Jantung Koroner dengan Sindrom Metabolik Pada Pasien Rawat Jalan di RS TK II Dr. Soepraoen Malang. Jurnal riset kefarmasian Indonesia.
Oktaviani, I., Setiadi, F., & Oktovina, M. N. (2024). Potensi Interaksi Obat Pada Pasien Penyakit Jantung Koroner Akut Di Rawat Inap Rumah Sakit Fatmawati Tahun 2023. Jurnal Farmasi Klinik Best Practice, 3(2).
Rahmi, S., & Marbun, N. (2025). Studi Potensi Interaksi Obat Pada Pasien Gagal Jantung Di Instalasi Rsu Sembiring Deli Tua. Variable Research Journal, 02(01).
Robiyatul, S., & Rahayuningsih, N. (2021). Kajian Interaksi Obat Aktual Pada Pasien Jantung Koroner Di Rumah Sakit X Kota Tasikmalaya. Jurnal Farmaku (Farmasi Muhammadiyah Kuningan), 6(1), 7-11.
Salasanti, C. D., Permana, M. D., & Idacahyati, K. (2024). Interaksi obat pada pasien sindrom koroner akut di RSUD Kota Banjar. Journal of Pharmacology and Clinical Pharmacy, 6(2), 1252. https://doi.org/10.36465/jop.v6i2.1252
Saputri, M., & Dewi, S. R. (2023). Potensi Interaksi Polifarmasi Pasien Jantung Koroner (PJK) di Rumah Sakit I.A. Moeis Samarinda. Jurnal Sains Dan Kesehatan, 5(2), 109–114. https://doi.org/10.25026/jsk.v5i2.1709
Septiani, A., & Rahmawati, F. (2025). Polypharmacy, drug-drug interaction and potentially inappropriate medication in hospitalized elderly patients with cardiovascular diseases in Wangaya Hospital. Pharmacy Journal, 21(2), 93730. https://doi.org/10.22146/farmaseutik.v21i2.93730
Setyaningsih, I., & Susilo, R. (2021). Gambaran Interaksi Obat Potensial Pada Resep Pasien Kardiovaskular Di Klinik Penyakit Dalam Rsud Gunung Jati Cirebon: Description Of Potensial Drug Interaction On Recipe Cardiovascular Patients At Internal Medicine Clinic RSUD Gunung Jati. Medimuh: Jurnal Kesehatan Muhammadiyah, 1(2), 163-170.
Sheikh-Taha, M., & Asmar, M. (2021). Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatrics, 21, 183. https://doi.org/10.1186/s12877-021-02183-0
Sultana, A., Singh, M., Kumar, A., Kumar, R., Saha, P., Shankar Kumar, R., & Kumar, D. (2022). To identify drug-drug interaction in cardiac patients in tertiary care hospitals. Journal of Research in Applied Sciences and Biotechnology, 1(3), 20. https://doi.org/10.55544/jrasb.1.3.20
Susilo, J., Sari, K., Susanti, R., Haryani, S., & Astuti, A. P. (2024). Kajian Naratif: Kesehatan Kardiovaskuler pada Masa Menopause Narative Review: Cardiovascular Health During Menopause. Indonesian Journal of Midwifery, 7(2). http://jurnal.unw.ac.id/index.php/ijm
Tamargo, J., Kjeldsen, K. P., Delpón, E., Semb, A. G., Cerbai, E., Dobrev, D., & Niessner, A. (2022).
Tanty, H. N., Utama, M. F. N., & Rosaqh, A. E. (2025). Polifarmasi dan Potensi Interaksi Obat: Studi pada Pasien Geriatri Hipertensi Rawat Inap di RS Islam Jakarta Pondok Kopi (Maret 2024-Februari 2025). Jurnal Farmasi IKIFA, 4(3), 103-115.
Vorobyeva, N. A., Komissarova, D. D., Vorontsova, A. S., & Vetoshkina, P. A. (2026). Carriage of CYP2C19 gene alleles and possible drug-drug interactions in patients with coronary artery disease. Arterial Hypertension, 32(1), 3213. https://doi.org/10.20996/1819-6446-2025-3213
Ye, L., Yang-Huang, J., Franse, C., Rukavina, T., Vasiljev, V., Mattace-Raso, F., & Raat, H. (2022). Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: A longitudinal study. BMC Geriatrics, 22, 536. https://doi.org/10.1186/s12877-022-03536-z
Young, E. H., Pan, S., Yap, A. G., Reveles, K., & Bhakta, K. (2021). Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS ONE, 16(8), e0255642. https://doi.org/10.1371/journal.pone.0255642
Zhao, M., Liu, C. F., Feng, Y., & Chen, H. (2022). Potential drug-drug interactions in drug therapy for older adults with chronic coronary syndrome at hospital discharge: A real-world study. Frontiers in Pharmacology, 13, 946415. https://doi.org/10.3389/fphar.2022.946415